Department of Chest Medicine, Taipei Veterans General Hospital, #201, Sec. Shih-Pai Road, Taipei, 11217, Taiwan.
School of Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan.
Eur J Med Res. 2024 Apr 20;29(1):243. doi: 10.1186/s40001-024-01840-5.
Despite vaccines' effectiveness in reducing COVID-19 infection rates and disease severity, their impact on critical patients presenting with acute respiratory failure is elusive. The aim of this study was to further investigate the influence of vaccination on mortality rates among severely ill COVID-19 patients experiencing acute respiratory failure.
This retrospective cohort study was carried out at a tertiary medical center in Taiwan. From April to September 2022, patients who tested positive for the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) through reverse transcription polymerase chain reaction (RT-PCR) and subsequently experienced acute respiratory failure were included in the study. Baseline characteristics, including vaccination history, along with information regarding critical illness and clinical outcomes, were gathered and compared between patients who received the vaccine and those who did not.
A total of 215 patients with COVID-19 exhibiting acute respiratory failure, as confirmed via RT‒PCR, were included in the analysis. Of this cohort, sixty-six (30.7%) patients died within 28 days. Neither administration of the vaccine nor achievement of primary series vaccination status had a significantly different effect on 28 day mortality, number of viral shedding events, acute respiratory distress syndrome (ARDS) incidence or other clinical outcomes. Patients who received the booster vaccine and completed the primary series showed a tendency of increased 28 days of ventilator-free status, though this difference was not statistically significant (p = 0.815).
Vaccination status did not significantly influence mortality rates, the occurrence of ARDS, or the viral shedding duration in COVID-19 patients with acute respiratory failure.
尽管疫苗在降低 COVID-19 感染率和疾病严重程度方面非常有效,但它们对出现急性呼吸衰竭的重症患者的影响仍不清楚。本研究旨在进一步探讨疫苗接种对急性呼吸衰竭的重症 COVID-19 患者的死亡率的影响。
这是一项在台湾一家三级医学中心进行的回顾性队列研究。2022 年 4 月至 9 月期间,通过逆转录聚合酶链反应(RT-PCR)检测出严重急性呼吸综合征冠状病毒 2(SARS-CoV-2)阳性并随后出现急性呼吸衰竭的患者被纳入研究。收集了患者的基线特征,包括疫苗接种史,以及有关危重病和临床结局的信息,并对接受疫苗和未接受疫苗的患者进行了比较。
共有 215 例经 RT-PCR 确诊为 COVID-19 急性呼吸衰竭的患者纳入分析。该队列中,66 例(30.7%)患者在 28 天内死亡。疫苗接种的实施或达到初级系列疫苗接种状态均对 28 天死亡率、病毒脱落事件数量、急性呼吸窘迫综合征(ARDS)发生率或其他临床结局没有显著影响。接受加强疫苗接种并完成初级系列疫苗接种的患者有延长 28 天无呼吸机状态的趋势,但差异无统计学意义(p=0.815)。
疫苗接种状态对急性呼吸衰竭的 COVID-19 患者的死亡率、ARDS 发生率或病毒脱落持续时间没有显著影响。